Scimega's Proven Approach to Site Selection & Patient Recruitment Attracting More Cutting-Edge Oncology Trials to Canada
Scimega Oncology, (www.scimega.com) the company behind the revolutionary Reverse Feasibility Program, announced it has been awarded four more cutting-edge oncology clinical trials at 35 centers across Canada, bringing the total to 12 in the last 18-months. Read full release...
Scimega awarded Phase 1b combination study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a novel folate receptor alpha (FRα)-targeting antibody-drug conjugate in combination with Liposomal Doxorubicin, Gemcitabine or Bevacizumab in adults with ovarian cancer and other FOLR1-positive tumors. The trial is active in five centers across Canada.
Scimega awarded Phase 2 randomized, double-blinded, controlled study of a small molecule selective inhibitor of HER2 vs. placebo in combination with Capecitabine and Trastuzumab in patients with pre-treated HER2+ breast carcinoma. The trial is active in 10 centers across Canada.
Scimega awarded Phase 3 study to evaluate the safety and efficacy of a development stage radiopharmaceutical imaging agent to detect clinically significant prostate cancer in men with biopsy proven low-grade prostate cancer who are candidates for active surveillance. The trial is active in 10 centers across Canada.